Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Novartis Combo On Track To Be First Targeted BRAF NSCLC Therapy

The EU's CHMP has granted a positive opinion for Novartis' combo of MEK inhibitor Mekinist and BRAF inhibitor Tafinlar for BRAF-positive non-small cell lung cancer patients.

Approvals Commercial

UCB Predicts Briviact Sales Of €450m by 2026; Plans New Partnerships

UCB says its early to mid-stage pipeline contains 10 promising breakthrough molecules, some of which it aims to partner with other pharma players as part of its open innovation strategy.

Companies Sales & Earnings

Deal Watch: Teva's Sol Barer Leads Buyout Of IO Start-up NexImmune

Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.

Commercial Deals

Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval

Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.

Approvals Biosimilars

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study

Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.

Clinical Trials Companies

UC's CRISPR Licensees Unbowed By Losing Initial US Patent Office Ruling

The US patent office's initial ruling on CRISPR patents that granted the Broad Institute a victory at the expense of the University of California caps the first major skirmish in what will be a long, drawn-out corporate legal battle.

Companies Legal Issues
See All
Advertisement
UsernamePublicRestriction

Register